Qiu LX, Chen T. Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease. World J Gastroenterol 2015; 21(4): 1099-1107 [PMID: 25632182 DOI: 10.3748/wjg.v21.i4.1099]
Corresponding Author of This Article
Long-Xin Qiu, PhD, School of Life Sciences, Longyan University, 1 North Dongxiao Road, Longyan 364000, Fujian Province, China. qlongxin@tom.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 28, 2015; 21(4): 1099-1107 Published online Jan 28, 2015. doi: 10.3748/wjg.v21.i4.1099
Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease
Long-Xin Qiu, Tong Chen
Long-Xin Qiu, Tong Chen, School of Life Sciences, Longyan University, Longyan 364000, Fujian Province, China
Long-Xin Qiu, Tong Chen, Key Laboratory of Preventive Veterinary Medicine and Biotechnology of Fujian Province, Longyan 364000, Fujian Province, China
Author contributions: Qiu LX and Chen T designed research; Qiu LX wrote the paper.
Supported by Science and Technology Planning Project of Longyan City, Grant No. 2012LY44; and Fujian Province, China, Grant No. 2010N0023.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Long-Xin Qiu, PhD, School of Life Sciences, Longyan University, 1 North Dongxiao Road, Longyan 364000, Fujian Province, China. qlongxin@tom.com
Telephone: +86-597-2793889 Fax: +86-597-2793889
Received: May 26, 2014 Peer-review started: May 27, 2014 First decision: June 27, 2014 Revised: July 11, 2014 Accepted: September 5, 2014 Article in press: September 5, 2014 Published online: January 28, 2015 Processing time: 245 Days and 16.3 Hours
Core Tip
Core tip: The aldose reductase (AR)/polyol pathway has recently been reported to be involved in the development of fatty liver disease (FLD) via various pathways. Some isoflavones have been reported to be potent AR inhibitors. Here, we review the anti-FLD actions of isoflavones and the proposed mechanism whereby isoflavones protect against FLD, with regard to the AR/polyol pathway. We propose that isoflavones block the AR/polyol pathway to suppress fructose production in the liver, improve peroxisome-proliferator-activated-receptor-α-mediated fatty acid oxidation, ameliorate cytochrome-P450-2E1-mediated oxidative stress, and attenuate AR/gut bacterial endotoxin-mediated cytokine overproduction, which in turn alleviates the progression of FLD.
